Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study

Area of Science:

• Hematology
• Oncology
• Bone Metabolism

Background:

• Bone density abnormalities after hematopoietic stem cell transplantation (HSCT) are not well understood.
• Multiple factors can influence bone health post-HSCT.
• Long-term quality of life can be affected by bone complications.

Purpose of the Study:

• To investigate the incidence and course of bone mineral density (BMD) changes after allogeneic HSCT.
• To identify risk factors for osteoporosis, fracture, and avascular necrosis post-HSCT.
• To evaluate the impact of immunosuppressive therapy on bone density.

Main Methods:

• Bone mineral densities (BMDs) at the hip, spine, and wrist were measured in 104 adults at 3 and 12 months post-HSCT.
• Clinical and laboratory variables were analyzed using univariate and multivariate analyses.
• Risk factors for osteoporosis, fracture, and avascular necrosis were determined.

Main Results:

• Significant hip BMD loss (4.2%) observed at 12 months post-HSCT in both men and women.
• Cumulative glucocorticoid dose and duration of immunosuppressive therapy (cyclosporine or tacrolimus) were associated with BMD loss.
• Nontraumatic fractures occurred in 10.6% and avascular necrosis in 9.6% of patients within 3 years.

Conclusions:

• Bone demineralization is common after allogeneic HSCT, accelerated by immunosuppressive therapy and glucocorticoids.
• Increased fracture and avascular necrosis incidence negatively impacts quality of life.
• Preventive strategies for bone loss are recommended post-HSCT.